Teladoc Health Return on Equity (ROE) Growth & History (TDOC)
Teladoc Health's return on equity was −13.93% for fiscal 2025.
View full Teladoc Health company overviewTeladoc Health annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −13.93% | +38.53 pp |
| 2024 | 2024-12-31 | −52.46% | −42.95 pp |
| 2023 | 2023-12-31 | −9.51% | +139.34 pp |
| 2022 | 2022-12-31 | −148.85% | −146.16 pp |
| 2021 | 2021-12-31 | −2.69% | +3.06 pp |
| 2020 | 2020-12-31 | −5.74% | +4.01 pp |
| 2019 | 2019-12-31 | −9.75% | +2.60 pp |
| 2018 | 2018-12-31 | −12.35% | +14.69 pp |
| 2017 | 2017-12-31 | −27.04% | +9.21 pp |
| 2016 | 2016-12-31 | −36.25% | +68.26 pp |
| 2015 | 2015-12-31 | −104.51% | — |
Teladoc Health quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −2.94% | −0.65 pp |
| Q1 2026 | 2026-03-31 | −4.69% | +1.68 pp |
| Q4 2025 | 2025-12-31 | −1.81% | +1.42 pp |
| Q3 2025 | 2025-09-30 | −3.52% | −1.31 pp |
| Q2 2025 | 2025-06-30 | −2.29% | +41.90 pp |
| Q1 2025 | 2025-03-31 | −6.37% | −2.83 pp |
| Q4 2024 | 2024-12-31 | −3.23% | −1.98 pp |
| Q3 2024 | 2024-09-30 | −2.21% | +0.28 pp |
| Q2 2024 | 2024-06-30 | −44.19% | −41.35 pp |
| Q1 2024 | 2024-03-31 | −3.55% | −0.54 pp |
| Q4 2023 | 2023-12-31 | −1.25% | +89.89 pp |
| Q3 2023 | 2023-09-30 | −2.49% | −1.28 pp |
| Q2 2023 | 2023-06-30 | −2.84% | +37.89 pp |
| Q1 2023 | 2023-03-31 | −3.01% | +49.99 pp |
| Q4 2022 | 2022-12-31 | −91.15% | −91.08 pp |
| Q3 2022 | 2022-09-30 | −1.21% | −0.68 pp |
| Q2 2022 | 2022-06-30 | −40.74% | −39.89 pp |
| Q1 2022 | 2022-03-31 | −53.00% | −51.74 pp |
| Q4 2021 | 2021-12-31 | −0.07% | +4.28 pp |
| Q3 2021 | 2021-09-30 | −0.53% | +1.51 pp |
| Q2 2021 | 2021-06-30 | −0.84% | +1.40 pp |
| Q1 2021 | 2021-03-31 | −1.26% | +1.68 pp |
| Q4 2020 | 2020-12-31 | −4.35% | −2.45 pp |
| Q3 2020 | 2020-09-30 | −2.04% | +0.00 pp |
| Q2 2020 | 2020-06-30 | −2.24% | +0.69 pp |
| Q1 2020 | 2020-03-31 | −2.94% | +0.05 pp |
| Q4 2019 | 2019-12-31 | −1.90% | +0.54 pp |
| Q3 2019 | 2019-09-30 | −2.04% | +0.66 pp |
| Q2 2019 | 2019-06-30 | −2.93% | +1.09 pp |
| Q1 2019 | 2019-03-31 | −2.99% | +1.31 pp |
| Q4 2018 | 2018-12-31 | −2.44% | +6.39 pp |
| Q3 2018 | 2018-09-30 | −2.69% | +4.71 pp |
| Q2 2018 | 2018-06-30 | −4.01% | +0.14 pp |
| Q1 2018 | 2018-03-31 | −4.30% | +1.15 pp |
| Q4 2017 | 2017-12-31 | −8.83% | −2.80 pp |
| Q3 2017 | 2017-09-30 | −7.41% | +7.70 pp |
| Q2 2017 | 2017-06-30 | −4.15% | +5.24 pp |
| Q1 2017 | 2017-03-31 | −5.45% | +3.45 pp |
| Q4 2016 | 2016-12-31 | −6.03% | +2.06 pp |
| Q3 2016 | 2016-09-30 | −15.10% | +8.21 pp |
| Q2 2016 | 2016-06-30 | −9.39% | — |
| Q1 2016 | 2016-03-31 | −8.91% | — |
| Q4 2015 | 2015-12-31 | −8.09% | — |
| Q3 2015 | 2015-09-30 | −23.31% | — |
Teladoc Health return on equity trends
Over the last five fiscal years, Teladoc Health's return on equity decreased from −5.74% to −13.93%, a change of −8.18 percentage points. The latest reported quarter, Q2 2026, shows −2.94%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teladoc Health source filings ↗